The infectious disease diagnostics firm will initially receive $40 million from CRG, most of which will go towards paying down existing debt.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The company said it will use the proceeds for various purposes, including working capital, capital expenditures, stock repurchases, dividends, and acquisitions.
The company took out the credit in connection with its $4.2 billion pending acquisition of electron microscopy firm FEI.
The firm did not disclose how it intended to use the $8 million, but said that it would provide temporary working capital.
The company's new $14 million facility refinances its original $6 million loan, and adds capital for new growth.
The company said the draw down is to provide working capital to use on a temporary basis.
The London-based firm plans to fund development and clinical trials for its point-of-care diagnostic test for serious blood infections.
The company replaced an existing $2.5 billion facility with an amended and restated $4 billion facility and entered into a new $7 billion facility.
The firm used about $1.68 billion of proceeds from the new term loans to repay existing secured credit facilities and transaction expenses.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.